[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Distribuidora Biolife SA de CV\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":102},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100556114","phase-2-impact-of-nano-pso-on-cognition-in-older-adults-with-mild-to-moderate-cognitive-impairment-100556114",false,"NCT06520878","Impact of NANO-PSO on Cognition in Older Adults with Mild to Moderate Cognitive Impairment","Impact of NANO-PSO (omega 5) Supplementation on Cognitive Abilities of Older Adults with Mild to Moderate Non-vascular Cognitive Impairment","COGMEG5","Inclusion Criteria:\n\n* Patients attended at the Hospital Español.\n* Patients of any gender who are 60 years or older.\n* Patients presenting with mild to moderate cognitive impairment.\n* Meet the diagnostic criteria for \\"probable dementia\\" of the National Institute on Aging and the Alzheimer's Association (NIA-AA) (2011).\n* Meet the criteria for the typical variant of Alzheimer's disease, specifically a specific clinical phenotype.\n* Progressive and gradual change in memory functions reported by the patient or the informant for at least 6 months.\n* Objective evidence of a hippocampal-type amnesic syndrome, based on significant impairment in the performance of episodic memory tests with established specificity for AD.\n* Subjects are primary and secondary school graduates and have the ability to complete cognitive capacity tests and other specified tests in the program.\n* Total score on the Hachinski Ischemic Scale (HIS) ≤ 4.\n* Patients who sign the informed consent.\n\nExclusion Criteria:\n\n* Patients with known allergy to any component of the NANO-PSO capsule (e.g., fish).\n* Patients with short bowel syndrome, bariatric surgery, or gluten reaction that may affect intestinal absorption.\n* Patients in palliative care with a life expectancy of less than 6 months according to the NECPAL scale.\n* Patients with terminality criteria established in the comprehensive palliative care management guide of Mexico.","ALL","60 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The objective of this randomized, triple-blind, placebo-controlled clinical trial is to compare NANO-PSO therapy against placebo in improving cognitive abilities in older adults with mild to moderate non-vascular cognitive impairment over six months of treatment. The primary questions it aims to answer are:\n\n• Does NANO-PSO therapy improve cognitive abilities in older adults with mild to moderate non-vascular cognitive impairment over six months of treatment compared to placebo?\n\nThe researchers will compare NANO-PSO therapy against placebo to see if it benefits the cognitive abilities of geriatric patients.\n\nParticipants will be required to:\n\n* Consume two capsules of NANO-PSO or placebo daily in the morning for six months.\n* Be evaluated monthly by phone to identify potential risks and ensure adherence to the treatment.\n* Be evaluated in person at 90 and 180 days of treatment.\n* The patient or primary caregiver must maintain a log to confirm daily dose consumption and will have a direct communication line with the attending physicians in case of questions about ingestion or possible adverse reactions.\n* At the end of the final patient evaluation, a quality questionnaire will be administered.",[27],"Cognition",[29,30,31,32,33],"NANO-PSO","Omega 5","Supplementation","Cognitive impairment","Antioxidants","RECRUITING","2025-02-03",{"date":37,"type":38},"2025-02-06","ACTUAL",{"date":40,"type":21},"2025-02-12",{"date":42,"type":21},"2025-12-01",{"name":44,"class":45},"Distribuidora Biolife SA de CV","INDUSTRY",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":54,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":46},"100558365","neuroprotective-effect-of-nano-pso-in-patients-who-used-to-consume-psychoactive-substances-100558365","NCT06550167","Neuroprotective Effect of (Nano PSO), in Patients Who Used to Consume Psychoactive Substances","Neuroprotective Effect of Omega (Nano PSO), Changes in Neurotrophic BDNF and VEGF, and Their Association With Cognitive Status in Patients Who Used to Consume Psychoactive Substances","Inclusion Criteria:\n\n* Patients who are multiple users of methamphetamines, cocaine, and cannabis with or without alcohol and tobacco, and have a history of at least 3 years of consumption.\n* Patients who accept informed consent to participate in the protocol.\n* Male gender.\n* Age between 18-50 years in the withdrawal phase currently in residential treatment\n\nExclusion Criteria:\n\n* Individuals under 18 years of age.\n* Patients who do not sign the informed consent.\n* Discharge of patients prior to the stipulated 6 months, requested by family members.\n* Patients with developed or known allergies.\n* Patients who are consuming NSAIDs, MAOIs (monoamine oxidase Inhibitor), active chronic inflammatory diseases, or any type of cancer","MALE","18 Years","50 Years",{"count":58,"type":21},80,[60],"NA","Addiction problems to psychoactive substances are becoming more frequent, which implies a serious health problem, with social, family and work repercussions. Participants with chronic consumption present important degeneration processes mediated by Neuroinflammation, oxidative stress and excitotoxicity. At the moment there is no effective treatment that can reduce the damage. The effectiveness of Omega 5 has been demonstrated in different disorders of the nervous system; However, very little has been elucidated about the mechanisms of regulation and activation in consumer patients. Omega 5 Nano-PSO has an important role in mechanisms of cell survival in different pathological events.\n\nIn this project aims to explain the possible mechanisms underlying the morphological changes and pathologies associated with oxidative stress and inflammation, since it could be a useful strategy to counteract the effects of substances of abuse on brain cells.\n\nOmega 5 (Nano PSO) will modify the levels of neurotrophic factors through the decrease in inflammation and reactive oxygen species in patient-consumers of substances, reducing neuronal death and therefore cognitive deterioration. Methodological design Type of study: Clinical trial, randomized controlled, double blind. Research Headquarters: This work will be carried out at the University Center for Health Science with the participation of the \"My family is waiting for me\" rehabilitation centers. Study Period: 2 years",[63,64],"Addiction;Drug(S);LSD","Neuroprotective",[66,64,67],"Addiction, Drug","pomegranate seed oil","2024-08-09",{"date":70,"type":38},"2024-08-12",{"date":72,"type":38},"2024-03-15",{"date":74,"type":21},"2027-03-15",{"name":44,"class":45},{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":83,"sex":84,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":46},"100549346","efficacy-of-nano-pso-therapy-in-menopause-100549346","NCT06432816","Efficacy of Nano-Pso Therapy in Menopause","Efficacy of Nano-Pso Therapy Compared to Placebo in the Control of Vasomotor Symptomatology in Early Menopause","Inclusion Criteria:\n\n* In perimenopause with vasomotor syndrome and score greater than 15 points staged with the MRS scale\n* They agree to participate and sign the consent informed.\n* Without prior treatment to relieve the symptoms of menopause.\n\nExclusion Criteria:\n\n* \\- With pharmacological and\u002For hormonal therapy prescribed for menopause symptoms.\n* With psychiatric pathologies such as anxiety and depression.\n* Hysterectomized patients or patients with induced menopause surgically early.\n* Smoking\n* Malnutrition or low weight determined by a BMI ≤ 18.5Kg\u002Fm2\n\nElimination criteria.\n\n* Who do not attend follow-up to provide their treatment the 1, 2, 3 and 4 months for application of the MRS scale\n* That they leave the study voluntarily.\n* Who present any serious adverse effect to the drug.",true,"FEMALE","45 Years","55 Years",{"count":88,"type":21},90,[60],"Vasomotor syndrome is prevalent in 85% of postmenopausal women, hormone therapy in menopause is first-line therapy, but 38% of patients have some contraindication for its use. The medications indicated in this population presents adverse reactions, such as dryness of the mucous membranes, and insomnia in patients, and triggers to abandoned treatment due to poor response to the drug. Aligned with the safety of patients, we wish to test pomegranate seed oil with nanotechnology (NANOPSO), which has been reported to have positive results at a central level, due to its antioxidant effect, which could impact women in climacteric in a positive way. The study involves the participation of 90 patients divided into two groups, where placebo or Nano-PSO will be administered for 60 days, with a total follow-up of 120 days. It is established that patients must not have received previous treatments for menopausal symptoms. Therefore, it is expected that therapy with NANO-PSO compared to placebo will be more effective in controlling vasomotor symptoms in early menopause after 6 months of treatment evaluated by the MRS scale.",[92,93],"Menopause","Vasomotor; Syndrome","2024-05-22",{"date":96,"type":38},"2024-05-29",{"date":98,"type":38},"2024-02-28",{"date":100,"type":21},"2026-07",{"name":44,"class":45},""]